IL6 and colitis: Studies have demonstrated that treatment with INT-747, an FXR agonist, in mice with colitis results in a reduction of pro-inflammatory cytokines such as Interleukin-1 beta (IL-1β) and Interleukin-6 (IL-6), as well as chemo-kines like C-C motif ligand 2 (41).